The only problem I see with FTO being such an emerging market is the market has no idea how to valuate this new breakthrough in cancer research and we're unable to get an easy peer comparison...
It feels like we're currently being valued based on pillars 2 and 3 with the market seeming to ignore the magnitude FTO holds because it simply doesn't understand it.
This is why I'm so bloody excited to have updates on pillar 1 going forward because it will give us a greater idea of the true outreach that FTO can have.
You can mark my words down for later, once the market realises the potential for FTO inhibition that's when RAC will have a serious, serious run.
The only problem I see with FTO being such an emerging market is...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
-0.020(1.59%) |
Mkt cap ! $204.3M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.26 | $1.21 | $80.80K | 65.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4453 | $1.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.25 | 2409 | 1 |
View Market Depth
| Last trade - 16.10pm 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.24 |
Change
-0.020 ( 1.59 %) |
||||
| Open | High | Low | Volume | ||
| $1.25 | $1.25 | $1.21 | 17239 | ||
| Last updated 15.56pm 01/05/2024 ? | |||||
| RAC (ASX) Chart |